The FDA approved Moderna’s mRNA-1010 (mFLUSIVA), marking the first FDA-authorized mRNA-based seasonal influenza vaccine. The decision came after a VRBPAC vote that determined benefits outweighed risks for adults aged 50–64, with Phase 3 data showing comparable serious safety events and consistent efficacy. In head-to-head comparisons versus the standard flu shot, Moderna reported a relative efficacy advantage, while noting increased reactogenicity—more frequent mild side effects such as injection-site pain. The approval adds a fourth FDA-approved product for Moderna and reinforces the company’s mRNA platform buildout. The vaccine now faces additional regulatory review in Europe, Canada, and Australia. U.S. post-market studies were part of the approval framework, aligning with renewed scrutiny in the U.S. for mRNA products. For biotech stakeholders, the approval is a concrete milestone for platform scale-up beyond COVID-era indications and provides a reference point for payer and provider adoption of next-generation vaccine manufacturing.